BioSpace News Archive

Medtronic plc, a global leader in healthcare technology, announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field and radiofrequency ablation and high density mapping catheter for the treatment of persistent atrial fibrillation.

StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2024, and will provide an update on its business operations.

Plus Therapeutics, Inc. announced that on May 8, 2024, it granted option awards to Charles Huang, the Company’s new Director of Capital Markets and Investor Relations.

Iovance Biotherapeutics, Inc. announced that on May 16, 2024, the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.

BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced that it has received a notification letter from the Nasdaq Stock Market LLC.

Oak Hill Bio and Chiesi announced that the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607, an investigational drug candidate being developed to treat complications of extremely premature birth, including bronchopulmonary dysplasia, a serious condition for which there are no approved therapies.

BioNTech SE held its Annual General Meeting , May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly.

CDx Diagnostics, Inc. announced the publication of a new study, Adjunctive Use of WATS-3D In Symptomatic GERD Patients Increases Detection of Barrett’s Esophagus and Dysplasia, in The American Journal of Gastroenterology.

Kamari Pharma today announced two presentations reporting results for its novel TRPV3 inhibitors, KM-001 (topical) and KM-023 (oral), were given at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) that is taking place May 15-18, 2024 in Dallas, TX, USA.

NervGen Pharma Corp. announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific Meeting being held on May 20-23, 2024, in San Juan, Puerto Rico